Evo­lus touts equal ef­fi­ca­cy for its Botox me-too drug in PhI­II Eu­ro­pean/Cana­di­an tri­als

Com­ing off the heels of a $80 mil­lion IPO to push its wrin­kle-re­duc­ing drug to­wards the mar­ket, Evo­lus is trot­ting out da­ta from a late-stage tri­al that com­pares its prod­uct to Botox.

The com­pa­ny’s in­ves­ti­ga­tion­al drug, prabot­u­lin­mu­tox­i­nA 900 kilo­dal­ton (kDa) neu­ro­mod­u­la­tor, met its pri­ma­ry end­points of non-in­fe­ri­or­i­ty to Botox at day 30 in pa­tients with mod­er­ate to se­vere glabel­lar lines (frown lines).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER